Exploring the Prognostic Role of Neurofilaments and SEMA3A in Multiple Sclerosis Progression

The transition from relapsing-remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS) is characterized by an increasing neurodegenerative component. Identifying biomarkers that distinguish these disease stages is crucial for early diagnosis and treatment optimization. This study aimed to compare serum levels of progranulin, interleukin-6 (IL-6), semaphorin 3A (SEMA3A), and neurofilaments between RRMS and SPMS patients and to investigate their correlation with clinical characteristics, including disability measured by the Expanded Disability Status Scale (EDSS). This observational study included 118 MS patients (63 RRMS and 55 SPMS). Serum biomarker levels were measured using an enzyme-linked immunosorbent assay (ELISA). Statistical analyses included group comparisons using non-parametric tests and correlation analyses using Pearson's correlation coefficient with multiple testing corrections. While demographic and clinical parameters significantly differed between groups (<i>p</i> < 0.001), biomarker levels showed no statistically significant differences (<i>p</i> > 0.05). However, in SPMS patients, SEMA3A correlated positively with neurofilaments (r = 0.359, <i>p</i> = 0.007), and progranulin correlated with IL-6 (r = 0.354, <i>p</i> = 0.008). No significant biomarker correlations with EDSS were found. Although absolute biomarker levels did not distinguish RRMS from SPMS, specific biomarker correlations may reflect processes relevant to disease progression and warrant further longitudinal validation.